ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
The genus Laggera: an extensive review of phytochemistry, pharmacology, clinical study, and chemical modification.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Laggera (Asteraceae) comprises medicinal plants traditionally used for treating inflammatory, infectious, and respiratory disorders. However, a comprehensive review of its phytochemistry and pharmacological potential is still limited. A systematic literature search was conducted across major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar, covering publications through April, 2026. Keywords such as "Laggera", "phytochemistry", "essential oil", "pharmacology", and "synthesis" were used. Relevant studies were selected based on their focus on chemical constituents, biological activities, clinical investigations, and chemical modifications. Data were categorized into phytochemical classes and pharmacological effects, and critically analyzed to provide an integrated overview of the genus. About 218 secondary metabolites have been identified, including terpenoids, flavonoids, phenolic acids, lignans, and others, with eudesmane-type sesquiterpenoids as the dominant class. Essential oils showed significant variability, with major constituents such as 2,5-dimethoxy-p-cymene and β-caryophyllene. Laggera constituents exhibited diverse pharmacological activities, including anticancer, antioxidant, anti-inflammatory, antimicrobial, antiviral, anti-insect, and organ protective effects. These activities are primarily associated with the signaling pathways, such as nuclear factor-kappa B (NF-κB), mitogen activated-protein kinase (MAPK), and vascular endothelial growth factor (VEGF). Preliminary clinical evidence reveals the therapeutic potential of L. pterodonta in respiratory diseases. In addition, semisynthesis and nanoformulation have been explored to enhance biological efficacy.
Indexed as
Identifiers
42606708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.